MAPT and Alzheimer disease: The clinical biomarker AD dataset encompasses measurements of brain structural integrity via MRI regions of interest (ROI), primary cognitive evaluations, the measurement of cell metabolism with FDG PET ROI averages, amyloid-beta load quantification through AV45 PET ROI averages, biomarkers for measuring tau load in the brain, axon-related microstructural parameters assessed with DTI ROI, CSF biomarkers for measuring tau and amyloid levels in cerebrospinal fluid, and additional data such as demographic information and APOE status including the number of APOE4 alleles.